By contrast, no significant difference in survival outcomes was observed between anti-EGFR vs R/T in the R-sided tumor group [median PFS 3.5 vs 3.3 months, HR 1.40 (95% CI 0.52-3.79), p=0.50; median OS 9.3 vs 4.8 months, HR 0.82 (95%CI 0.29-2.30), p=0.70]. This evidence concerns the gene EGFR and neoplasm.